Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer. Print this page , }) d( u$ ~ }% t3 @& R5 j; _/ q
9 p' y8 T# u; t6 v6 G" o. P
) G8 |9 L0 C" w# x$ Q- tSub-category:
2 J. U9 a7 c" s4 a7 x- E: e( B0 fMolecular Targets
* c2 z, J! |2 Z; T; M2 z, P& o) M
( r& C, I) h n* | U: R4 a
Category:' \6 w$ C8 Z, R! V4 G" c! Y
Tumor Biology : w; }% G' l% N; ]0 f* F
$ i+ n: v+ o* a, n- G3 F) U1 _3 c8 k) R5 D
Meeting:/ K- Y4 v% `% q3 R, K0 ?
2011 ASCO Annual Meeting
1 y! t$ J: h- J6 x3 f* B$ M# J3 P1 h1 H' @
& M( o. @: i( i, k4 T- A3 }) \5 BSession Type and Session Title:8 y1 U$ a0 ]! ~+ Q9 ~0 U' U
Poster Discussion Session, Tumor Biology " \3 |# w5 ?0 ^8 F( A
' t% o( d c! w: q; A$ U
* E) Y0 w" x% \' v. LAbstract No:
4 e/ V; o r5 n10517 5 T2 t9 _4 j5 B5 g
9 V7 z$ g+ h3 s; S/ |( E
# d0 i! K* W/ h# I" ]9 _Citation:6 ` S! e" y+ |* z( i& [
J Clin Oncol 29: 2011 (suppl; abstr 10517)
/ Z( M, m; O* j) x( j+ A+ Z: F+ W$ f' k; y( j5 I& }
O% G/ y* w0 B3 u2 L. H
Author(s):
; ^4 S+ i" R' m+ tJ. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China 4 d2 g5 Z- f9 s& ^; ^+ o
, [" O9 q: T; @+ k- i4 Z0 W; \
; \. b6 u0 u8 `! Q; G% [( g
: L3 |- l1 F, v( X* x7 uAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.$ m( p7 S( i& K; V
) h1 R$ N$ }( R4 e' M
Abstract Disclosures
, D6 F0 A" p6 P9 I1 _7 L8 I
: m* d) u; s& n7 `4 Z# l" w( gAbstract:9 F0 J" p4 t& Q5 Z) S% j
- V: i9 J+ ]3 {/ W/ ~+ }
, [, k' ~, `$ v9 H1 p' m
Background: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation." y& O5 Y5 z: `$ }
9 n$ Z0 ~0 u& @, @. |% l% R ^$ t+ ~9 E' E1 ]+ _: H+ S, {
|
显身卡
